Announced Thu, 23 Jul · 14:20 IST
Board meeting on July 30 to consider Q1 FY27 results
Results View source PDF
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.0%1-day move
₹1140.90
prior close
₹1116.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.3-0.4-0.7-3.0-0.5————————
Up moveDown movePending
AI summary
Alivus Life Sciences (formerly Glenmark Life Sciences) has informed BSE and NSE that its Board of Directors will meet on July 30, 2026 to consider and approve the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The trading window for designated persons has been closed from July 1 to August 1, 2026 in line with insider trading rules. No financial numbers have been disclosed yet.
Likely market impact
Routine procedural filing. Actual Q1 FY27 numbers will be known after the board meeting on July 30, 2026.